Suggested remit: To appraise the clinical and cost effectiveness of roxadustat within its marketing authorisation for treating anaemia in people with chronic kidney disease.
Status In progress
Decision Selected
Process STA 2018
ID number 1483

Provisional Schedule

Expected publication 01 June 2022

Project Team

Project lead Thomas Feist

Email enquiries


Companies sponsors Astellas Pharma Ltd
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Care UK
  UK Renal Pharmacy Group
Professional groups Anaemia Nurse Specialist Association
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
26 January 2022 - 16 February 2022 Draft guidance
08 December 2021 Committee meeting: 1
19 April 2021 Invitation to participate
12 January 2021 In progress. Topic is in progress
05 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of roxadustat for treating anaemia in people with chronic kidney disease. Please note that following on from a request received from the company to reschedule the initial date proposed by NICE, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-Apr 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2021.
09 September 2020 (10:00) Scoping workshop
14 July 2020 - 11 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2020 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of roxadustat for treating anaemia in people with chronic kidney disease ID1483. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that markets roxadustat, NICE has agreed that holding a scoping exercise at this time is not appropriate. Consequently, the scoping workshop arranged for the 17 March 20 will be cancelled. We apologise for any inconvenience this may cause. The workshop and consultation will be rescheduled to take place later in 2020. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on

For further information on our processes and methods, please see our CHTE processes and methods manual